Fig. 1: Progression-free survival (PFS) and overall survival (OS) in the whole cohort (A) and workflow (B). | Nature Communications

Fig. 1: Progression-free survival (PFS) and overall survival (OS) in the whole cohort (A) and workflow (B).

From: Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

Fig. 1

Patients in the PFS curve are censored at the date of last news if not in progression, while patients in the OS curve are censored at the date of last news if alive. NR: not reached; UM: uveal melanoma; 3w: 3 weeks; 12w: 12 weeks. Source data are provided as a Source Data file.

Back to article page